LSBio The Immunohistochemistry Antibody Company
  • Home
  • Antibodies
    • Primary Antibodies
    • Secondary Antibodies
    • IHC-plus Antibodies
    • Isotype Control Antibodies
  • ELISA Kits
    • All Kits
    • Sandwich ELISA Kits
    • EIA Kits
    • Cell-Based ELISA Kits
    • DNA-Binding ELISA Kits
  • Services
    • Immunohistochemistry Studies
    • Tissue Cross-Reactivity Screening
  • Distributors
  • Resources
    • About our Tissue Bank
    • Customer Support
    • How to Buy
    • IHC-plus Protocol
    • LSBio Media
    • Publications
    • Antibody Reports
  • Company
    • About LifeSpan
    • Press Releases
    • Holiday Schedule
    • Contact Us
  • View Cart

Anti-BRCA1 Antibody (aa1634-1863) LS-C182772

See our new BRCA1 ELISA Kits
Human Phospho-BRCA1 Cell-Based ELISA Kit - LS-F1725
Human BRCA1 Cell-Based ELISA Kit - LS-F1833
(kits do not necessarily contain the antibody listed on this page)

Ordering

Wt. Vol. Conc. Price
100 µg 500 µl 0.1 mg/ml $650

LSBio (Direct) LSBio (Direct)
206-374-1102
866-206-6909
Orders@LSBio.com
 

100% Guaranteed 100% Guaranteed
Sheep Polyclonal (IgG) to Human BRCA1
Human
IHC
Unconjugated

Details

Human BRCA1
Sheep
Human (tested or 100% immunogen sequence identity)
IgG Polyclonal
Immunoaffinity purified

Applications

IHC (5 - 15 µg/ml)

Specificity and Use

BRCA1 antibody was raised against recombinant corresponding to aa1634-1863 from C-terminus of human BRCA1 expressed in E.coli.
aa1634-1863
Human BRCA1.

Packaging

Lyophilized from PBS, trehalose
500 µl Sterile PBS
Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 12 months at -20°C.
For research use only.

About BRCA1

P38398 NM_007294 NP_009225.1

BRCA1 Antibody, BROVCA1 Antibody, BRCC1 Antibody, Breast cancer 1, early onset Antibody, PPP1R53 Antibody, PSCP Antibody, PNCA4 Antibody, RING finger protein 53 Antibody, RNF53 Antibody, BRCAI Antibody, Breast cancer 1 early onset Antibody, IRIS Antibody

Associated with several familial cancers, including breast cancer, ovarian cancer, and prostate cancer. The cumulative lifetime risk of breast cancer for women who carry mutations in BRCA1 is approximately 92%, while the cumulative lifetime risk for noncarriers is estimated to be 10%. BRCA1 and BRCA2 participate together in a pathway (or pathways) associated with the activation of double-strand break repair and/or homologous recombination.

Requested From: United States
Date Requested: 10/23/2014

Get Social With Us! Follow us on Facebook Follow us on Google+ Follow us on LinkedIn
Copyright © 2014 LifeSpan BioSciences, Inc. All Rights Reserved